PRESS-RELEASE filed Jul 30, 2026 at 06:30 ET
Regeneron reported Q2 2026 non-GAAP EPS of $14.29, a 40.1% beat vs consensus of $10.20, on total revenue of $4.29B (+17% YoY), driven by strong Dupixent (+38%), EYLEA HD (+52%), and Libtayo (+30%) sales. The Sanofi Development Balance was fully repaid, which will boost collaboration profits starting Q3, and the company raised its full-year guidance on gross margins and narrowed R&D and SG&A ranges. The massive EPS beat and raised fundamentals support a bullish read, though GAAP net income declined 7% due to a $127M IPR&D charge and higher tax rate.